4.6 Article

Inhibition of ERK and p38 MAP kinases inhibits binding of Nrf2 and induction of GCS genes

Journal

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1006/bbrc.2000.3830

Keywords

gamma-glutamylcysteine synthetase; GCS; MAPK; kinase; EpRE/ARE; Nrf2; transcription; phosphorylation; signal transduction; JunD

Funding

  1. NCI NIH HHS [CA57549, T32-CA09471] Funding Source: Medline
  2. NIEHS NIH HHS [ES09749] Funding Source: Medline

Ask authors/readers for more resources

Genes encoding the catalytic (GCS(h)) and regulatory (GCS(1)) subunits of human gamma -glutamylcysteine synthetase (gamma GCS), which catalyzes the rate limiting step in glutathione synthesis, are up-regulated in response to xenobiotics through Electrophile Response Elements (EpREs). Exposure of HepG2 cells to the GCS-inducing agent, Pyrrolidine dithiocarbamate (PDTC), results in ERK and p38 MAP kinase activation. Inhibition of ERK or p38 kinases by PD98059 or SB202190, respectively, results in similar to 50% reduction in GCS gene induction, while simultaneous inhibition completely eliminates induction. Induction of GCS expression is associated with an increase in Nrf2 and JunD binding to GCS EpREs. Pretreatment with the MAPK inhibitors significantly reduces binding of both transcription factors. These studies indicate that ERK and p38 contribute to the transcriptional up-regulation of the GCS subunit genes following PDTC treatment. Furthermore, supershift analyses suggest that binding of Nrf2 and JunD to the EpRE is a downstream consequence of ERK and p38 phosphorylation events. (C) 2000 Academic Press.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available